Erste Asset Management Trims Vertex Pharmaceuticals Stake

Hedge fund reduces position in biotech company by 8.6% in Q3

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

Erste Asset Management GmbH, a German investment management firm, reduced its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 8.6% during the third quarter of 2025, according to a recent 13F filing with the Securities and Exchange Commission (SEC). The firm now owns 67,517 shares of the pharmaceutical company's stock, valued at $26,685,000.

Why it matters

Vertex Pharmaceuticals is a leading biotech company focused on developing treatments for serious diseases, particularly cystic fibrosis. The company's stock has been a strong performer, and institutional investors like Erste Asset Management closely monitor its progress. This reduction in Erste's position could signal a shift in investor sentiment or portfolio rebalancing, which is worth tracking for Vertex's shareholders and the broader biotech industry.

The details

According to the 13F filing, Erste Asset Management sold 6,386 shares of Vertex Pharmaceuticals during the third quarter, reducing its total position by 8.6%. The firm's remaining stake in Vertex is valued at $26,685,000. Vertex Pharmaceuticals is known for its innovative cystic fibrosis treatments and has a strong pipeline of other drug candidates in development.

  • Erste Asset Management filed its 13F report for the third quarter of 2025 on February 27, 2026.

The players

Erste Asset Management GmbH

A German investment management firm that manages assets for institutional and retail clients.

Vertex Pharmaceuticals Incorporated

A Boston-based biotechnology company focused on developing therapies for serious diseases, particularly cystic fibrosis.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Erste Asset Management's position in Vertex Pharmaceuticals is a noteworthy development that could signal broader shifts in investor sentiment around the biotech company. However, Vertex's fundamentals remain strong, and the company continues to make progress in its drug development pipeline, which will be closely watched by investors and analysts.